Pembrolizumab

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab
December 14, 2017Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab
November 10, 2017[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma
June 07, 2016Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.

Pembrolizumab Improves Long-term Survival in Advanced Melanoma
June 03, 2016Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.
Immunotherapy Drugs Shows Early Promise in Treating Tumors of Rare, Virus-linked Skin Cancer
May 11, 2016Half of 25 patients with Merkel cell carcinoma treated with pembrolizumab experienced significant tumor shrinkage that lasted almost 3 times longer than conventional chemotherapy, and some had no remaining disease after treatment.

Pembrolizumab Achieves Response and Increased Survival in Melanoma
May 11, 2016Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- National Cancer Drug Shortages Unknown to Many Patients
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |